43 results on '"Camidge, D R"'
Search Results
2. Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial: 1330
3. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
4. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer
5. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer
6. Abstract CT169: A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors
7. Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial
8. The epidemiology of self-poisoning in the UK
9. The causes of dysphagia in carcinoma of the lung
10. Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations : New Results from the Global IMMUNOTARGET Registry
11. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
12. Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) : An Update of ASCEND-1: Metastatic Non-Small Cell Lung Cancer
13. Ceritinib (LDK378) for treatment of patients with ALK-rearranged (ALK plus) non small cell lung cancer (NSCLO) and brain metastases (BM) in the ascend-1 trial
14. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors
15. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
16. Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1
17. The impact of socioeconomic status on access to cancer clinical trials
18. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
19. A chronology of cancer
20. Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
21. Hospital admissions and deaths relating to deliberate self-harm and accidents within 5 years of a cancer diagnosis: a national study in Scotland, UK
22. Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data
23. Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development
24. Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies
25. Cloning of Drosophila beta-adaptin and its localization on expression in mammalian cells.
26. 1169PRORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial.
27. 437PPT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors.
28. A Phase I open label study of continuous oral treatment with BIBF 1120 together with carboplatin and paclitaxel treated patients with non-small cell lung cancer (NSCLC).
29. Erlotinib (E) as a single agent or intercalated with carboplatin and paclitaxel (ECP) in an EGFR biomarker-selected, previously untreated NSCLC population.
30. MO2-15-1 [Encore] Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions.
31. Crizotinib in ROS1 -rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
32. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
33. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
34. O1-4-2 [Encore] Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L.
35. 107O Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001.
36. 106O Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial.
37. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
38. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
39. A rational approach to the development of drug combinations in thoracic oncology.
40. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
41. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.
42. Is FISH floating or still swimming in the lung cancer ocean?
43. Genetic susceptibility to tuberculosis in Africans: a genome-wide scan.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.